Crossmark

Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia

Crossref DOI link: https://doi.org/10.1038/s41409-022-01817-0

Published Online: 2022-09-23

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Song, Ga-Young https://orcid.org/0000-0002-5203-2982
Kim, TaeHyung

Ahn, Seo-Yeon

Jung, Sung-Hoon

Kim, Mihee

Yang, Deok-Hwan https://orcid.org/0000-0002-8167-8520
Lee, Je-Jung https://orcid.org/0000-0002-4635-5697
Choi, Seung Hyun

Kim, Mi Yeon

Jung, Chul Won

Jang, Jun-Ho

Kim, Hee Je https://orcid.org/0000-0003-4098-3366
Moon, Joon Ho https://orcid.org/0000-0003-3756-796X
Sohn, Sang Kyun

Won, Jong-Ho

Park, Seong-Kyu

Kim, Sung-Hyun

Zhang, Zhaolei https://orcid.org/0000-0002-7303-6472
Ahn, Jae-Sook https://orcid.org/0000-0003-3078-5024
Kim, Hyeoung-Joon https://orcid.org/0000-0002-0998-1090
Kim, Dennis Dong Hwan https://orcid.org/0000-0003-2640-4911
License Information

Text and Data Mining valid from 2022-09-23

Version of Record valid from 2022-09-23
More Information

Article History

Received: 14 January 2022

Revised: 16 August 2022

Accepted: 22 August 2022

First Online: 23 September 2022

Competing interests

: The authors declare no competing interests.

: This retrospective study was approved by the institutional ethics committee of each participating institution and conducted in accordance with the Declaration of Helsinki. The committee waived the need for informed patient consent because of the retrospective nature of the work.

Document is current

Any future updates will be listed below